ANGO
AngioDynamics Inc
Q3 2025 Report
AngioDynamics Inc (ANGO) Third Quarter Financial Results 2025: Strong Growth in MedTech Segment...
Read full report
Executive Summary
AngioDynamics reported QQ1 2026 revenue of $75.71 million, up 6.7% year-over-year, with gross profit of $41.86 million and a gross margin of 55.29%. However, operating income remained negative at -$5.25 million and net income declined to -$10.90 million, translating to an EPS of -$0.26. The quarter delivered revenue momentum but profitability and cash flow remained under pressure due to elevated operating expenses. The company ended the quarter with roughly $38.76 million in cash and equivalents and a net cash position of about -$38.8 million in net debt terms, highlighting a liquidity runway but a need to convert top-line strength into operating income. Looking ahead, management emphasized execution on growth initiatives and portfolio resilience, with a focus on product introductions (e.g., NanoKnife, Solero) and international expansion, while cost control remains a critical lever for margin recovery. Investors should monitor pipeline progression, reimbursement dynamics, and ongoing SG&A discipline as key catalysts for a turnaround.
Key Performance Indicators
Revenue
75.71M
QoQ: 5.15% | YoY:6.67%
Gross Profit
41.86M
55.29% margin
QoQ: 7.72% | YoY:16.46%
Operating Income
-5.25M
QoQ: -29.51% | YoY:9.65%
Net Income
-10.90M
QoQ: -147.40% | YoY:18.93%
EPS
-0.26
QoQ: -136.36% | YoY:21.21%
Revenue Trend
Margin Analysis
Key Insights
Revenue: $75,711,000, YoY +6.7%, QoQ +5.15%; Gross Profit: $41,857,000, YoY +16.46%, QoQ +7.72%; Gross Margin: 55.29%; Operating Income: -$5,245,000, YoY +9.65% (still negative), QoQ -29.51%; EBITDA: -$5,245,000; Net Income: -$10,903,000, YoY +18.93% (negative bottom line but less negative vs prior year), QoS: EPS -$0.26, YoY +21.21%, QoQ -136.36%; Free Cash Flow: -$16.65 million; Cash and equivalents: $38.76 million; Net debt: -$38.76 million; Total assets: $265.64 million; Total equity: $178.8...